JPMorgan analyst Lilia-Celine Lozada downgraded Treace Medical (TMCI) to Underweight from Neutral with a price target of $5, down from $8. The company’s earnings update is “disappointing” as the better than expected quarter was overshadowed by a reset to guidance as softness in the foot and ankle market, a shift away from Lapiplasty, and a mix headwind from new launches are set to pressure revenues in the near-term, the analyst tells investors in a research note. The firm sees multiple headwinds pressuring Treace Medical’s near-term growth “and no clear timing of resolution.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMCI:
- Treace Medical Concepts Reports Q3 2025 Financial Results
- Treace Medical cuts FY25 revenue view to $211M-$213M from $224M-$230M
- Treace Medical reports Q3 EPS (26c), consensus (27c)
- Treace Medical’s Innovative Foot Correction Study: A Potential Game-Changer?
- Treace Medical price target lowered to $7 from $8 at Truist